Mettez-vous hors ligne avec l'application Player FM !
Obesity Tx End-Around With Skye Bioscience's Punit Dhillon
Manage episode 446175921 series 2739469
We love to hear from our listeners. Send us a message.
While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (CB1) inverse agonist monlunabant last month, Skye Bioscience Chairman and CEO Punit Dhillon is shaking it off. He's confident that his company's antibody-based approach to CB1 inhibition will make a moot point of the neuropsychiatric side effects that put a damper on Novo's data. On this episode of the Business of Biotech, we're digging into the uber-hot business of weight loss therapeutics and going deep with Dhillon on why Skye's blood/brain barrier-obeying antibody might turn the GLP-1 and small molecule approaches to obesity on their ears. Over the course of the conversation, we explore the ins-and-outs of the business of metabolic health, a space that's churning out one blockbuster after another.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Chapitres
1. Obesity Tx End-Around With Skye Bioscience's Punit Dhillon (00:00:00)
2. Metabolic Health and Biotech Innovations (00:00:04)
3. Biotech Leadership and Strategic Hiring (00:04:43)
4. Challenging the Status Quo in Biotech (00:17:49)
5. Innovative Approaches to Weight Loss (00:26:40)
6. Developing CB1 Inhibition for Weight Loss (00:32:50)
7. Innovative Approach to Obesity Treatment (00:42:58)
8. Balance Between Fitness and Pharmacotherapy (00:56:08)
242 episodes
Manage episode 446175921 series 2739469
We love to hear from our listeners. Send us a message.
While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (CB1) inverse agonist monlunabant last month, Skye Bioscience Chairman and CEO Punit Dhillon is shaking it off. He's confident that his company's antibody-based approach to CB1 inhibition will make a moot point of the neuropsychiatric side effects that put a damper on Novo's data. On this episode of the Business of Biotech, we're digging into the uber-hot business of weight loss therapeutics and going deep with Dhillon on why Skye's blood/brain barrier-obeying antibody might turn the GLP-1 and small molecule approaches to obesity on their ears. Over the course of the conversation, we explore the ins-and-outs of the business of metabolic health, a space that's churning out one blockbuster after another.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Chapitres
1. Obesity Tx End-Around With Skye Bioscience's Punit Dhillon (00:00:00)
2. Metabolic Health and Biotech Innovations (00:00:04)
3. Biotech Leadership and Strategic Hiring (00:04:43)
4. Challenging the Status Quo in Biotech (00:17:49)
5. Innovative Approaches to Weight Loss (00:26:40)
6. Developing CB1 Inhibition for Weight Loss (00:32:50)
7. Innovative Approach to Obesity Treatment (00:42:58)
8. Balance Between Fitness and Pharmacotherapy (00:56:08)
242 episodes
Tous les épisodes
×Bienvenue sur Lecteur FM!
Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.